Fig. 2
From: Integrated multiomic approach for identification of novel immunotherapeutic targets in AML
Protocol Optimization Steps using OCI-AML3 cells. A Protocol optimization steps for Glyco-CSC examined. B Bar graph of number of deamidation sites from the OCI-AML3 cell line according to our improved protocol versions. No. 6 yielded > 500 deamidation sites, representing 252 proteins. C & D Probability of N-glycosylation events being localized at the expected position of identified peptides in each group (Loc. Prob., threshold ≥ 0.75) for CD proteins (C) and Non-CD proteins (D). E Comparison of detected proteins between Glyco-CSC, Lys-CSC and Cys-Glyco-CSC. Numbers refer to detected proteins. F Detailed view of detected proteins in comparison experiment summarized in (E). Nodes representing CD proteins (black) and non-CD proteins (red). Thickness of connecting lines is proportional to the number of peptides identified for the associated protein and size of the node indicates the number of transmembrane domains (TMs). Proteins with ≥ 10 TMs were limited to 10